To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Fundamental basic laboratory, clinical, and population research are the foundation for all of Karmanos Cancer Institute's Research Programs, which are ultimately directed toward the prevention, early detection or treatment of cancer.
Our Programs include: Tumor Biology and Microenvironment (TBM), Molecular Imaging (MI), Molecular Therapeutics (MT) and Population Studies and Disparities Research (PSDR).
The cancer focus is comprehensive, and encompasses etiology, epidemiology, and prevention, early detection (particularly focused on minority populations), basic and translational research, clinical care (based upon multidisciplinary teams) and clinical research (including investigator-initiated and cooperative group clinical trials).
WDET John Wallbillich, M.D. , gynecologic oncologist and member of the Gynecologic Oncology Multidisciplinary Team at Karmanos, explained the stat...
Michigan Chronicle has named 50 trailblazing women to its annual Women of Excellence List . This includes the Barbara Ann Karmanos Cancer Institut...
WWJ On this year’s World Cancer Day, Jay Yang, M.D. , hematologist, medical oncologist and leader of the Hematology Oncology Multidisciplina...